2025 Full Event Guide

Thank you to our speakers, sponsors, and delegates who joined us in 7th Inflammasome Therapeutics Summit for the summit!

If you are interested in the next event, please get in touch at info@hansonwade.com

2025 Event Guide

With 20+ expert speakers and 3 days of inflammasome content and networking opportunities, the 7th Inflammasome Therapeutics Summit full event guide showcases industry case studies, insights, and clinical data that will help drive your programs forward. Get premium access to our 2025 Event Guide and see the full list of speakers, session highlights, and partnering opportunities that you missed.

7th Inflammasome Therapeutics Summit Brochure

What Can You Missed?

  • 20+ Inflammasome Expert Speakers
  • 10+ C-Suites & Vice Presidents
  • 5+ Pivotal Clinical Readouts
  • 3 Interactive Workshops
  • 8+ Hours of Networking

Having trouble downloading the brochure? Let us know and we’ll email it to you instead

2025 Companies on the Program

2025 Speaker Spotlight

Alan Watt, President & Chief Scientific Officer - 7th Inflammasome Therapeutics Summit

Alan Watt

President & Chief Scientific Officer

NodThera Ltd.

Cynthia Lebeaupin, Senior Scientist, Inflammation & Immunology -7th Inflammasome Therapeutics Summit

Cynthia Lebeaupin

Senior Scientist, Inflammation & Immunology R&D

Pfizer

Lauren Martens, Vice President - Biology - 7th Inflammasome Therapeutics Summit

Lauren Martens

Vice President, Biology

Neumora Therapeutics, Inc.

Marc Pelletier, Novartis - 7th Inflammasome Therapeutics Summit

Marc Pelletier

Translational Immune Oncology, Associate Director

Novartis AG

Paul Ashton, Inflammasome Therapeutics - 7th Inflammasome Therapeutics Summit

Paul Ashton

Chief Executive Officer

Inflammasome Therapeutics

2025 Audience Breakdown

Seniority Of Attendees - 8% Chief, 15% Director, Head 8%, 6% President, 2% professor, 17% scientist 11%other - Types of companies attending, 65% Pharma & Biotech, 23% Service Providers & Other, 12% Academic - 7th Inflammasome Therapeutics Summit
Types of companies attending, 65% Pharma & Biotech, 23% Service Providers & Other, 12% Academic - 7th Inflammasome Therapeutics Summit

*Statistics Taken from 6th Inflammasome Therapeutics Summit